The impact of Perioperative Dexmedetomidine usage in prevention of Acute Kidney Injury in patients undergoing Whipple operations ( randomized control study )

开始日期2024-04-01

申办/合作机构

National Liver Institute, Egypt

PACTR202405826827983 / Recruiting临床4期IIT

Analgesic Effect of Postoperative Ultrasound Guided External Oblique Intercostal Plane Block versusPatient Controlled Analgesia in Surgeries of Subcostal Incisions

开始日期2024-02-01

申办/合作机构

National Liver Institute, Egypt

PACTR202401852393337 / Recruiting临床4期IIT

Analgesia Nociceptive Index for Nociception Monitoring in Cirrhotic Patients Undergoing Hepatic Resection: Randomized Control Trial

开始日期2022-03-01

申办/合作机构

National Liver Institute, Egypt

100 项与 National Liver Institute, Egypt 相关的临床结果

登录后查看更多信息

0 项与 National Liver Institute, Egypt 相关的专利（医药）

登录后查看更多信息

项与 National Liver Institute, Egypt 相关的文献（医药）

2024-04-01·The Lancet Gastroenterology & Hepatology

Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update

Review

作者: Desalegn, Hailemichael ; Waked, Imam ; Al-Mahtab, Mamum ; Cheinquer, Hugo ; Muljono, David H ; Hiebert, Lindsey ; Ward, John W ; Aggarwal, Rakesh ; Marshall, Alison D ; Grebely, Jason ; Thomas, David L ; Onyekwere, Charles A ; Dirac, Mae Ashworth ; Han, Hannah ; Lesi, Olufunmilayo ; Palayew, Adam ; Cooke, Graham S ; Tanaka, Yashuito ; Mbendi, Charles ; Poovorawan, Kittiyod ; Lazarus, Jeffrey V ; Cunningham, Evan ; Flower, Barnaby ; de Araujo, Alexandre ; Ivanchuk, Iryna ; Chulanov, Vladimir ; Jeong, Sook-Hyang ; Khue, Pham M ; Alcantara-Payawal, Diana ; Sanchez-Avila, Juan F ; Jia, Jidong ; Hamid, Saeed ; Pimenov, Nikolay ; Malyuta, Ruslan

The top 20 highest burdened countries (in disability-adjusted life years) account for more than 75% of the global burden of viral hepatitis. An effective response in these 20 countries is crucial if global elimination targets are to be achieved. In this update of the Lancet Gastroenterology & Hepatology Commission on accelerating the elimination of viral hepatitis, we convene national experts from each of the top 20 highest burdened countries to provide an update on progress. Although the global burden of diseases is falling, progress towards elimination varies greatly by country. By use of a hepatitis elimination policy index conceived as part of the 2019 Commission, we measure countries' progress towards elimination. Progress in elimination policy has been made in 14 of 20 countries with the highest burden since 2018, with the most substantial gains observed in Bangladesh, India, Indonesia, Japan, and Russia. Most improvements are attributable to the publication of formalised national action plans for the elimination of viral hepatitis, provision of publicly funded screening programmes, and government subsidisation of antiviral treatments. Key themes that emerged from discussion between national commissioners from the highest burdened countries build on the original recommendations to accelerate the global elimination of viral hepatitis. These themes include the need for simplified models of care, improved access to appropriate diagnostics, financing initiatives, and rapid implementation of lessons from the COVID-19 pandemic.

2024-01-01·Physiotherapy Research International

The difference in multifidus muscle morphology and motor control in non‐specific low back pain with clinical lumbar instability and healthy subjects: A case‐control study

Article

作者: Hassan, Karima Abdelaty ; Abdelaty, Eman Masry ; Lotfy, Osama ; Shendy, Salwa

AbstractBackgroundLow back pain (LBP) with clinical lumbar instability (CLI) is considered a subgroup of back pain. Poor core stability function and/or lack of motor controls are thought to play a role in inappropriate inter‐segmental movements and pain. There is no study investigating the changes in the lumbar multifidus muscle (LMM) morphology and motor control in this subgroup of patients.ObjectiveTo assess motor control components and morphological changes of LMM in the patients suffering from chronic nonspecific low back pain (CNSLBP) with CLI.DesignObservational case‐control study.MethodsThirty‐two patients suffering from (CNSLBP) with CLI and 32 healthy individuals were included. The muscle force element of lumbar motor control was assessed by using (the active straight‐leg raise test, leg lowering test, and Trendelenburg test). Ultrasonography was used to assess changes in the LMM morphology.ResultsThere was a significant decrease in motor control (p = 0.0001), an increase in LMM fatty infiltration (p = 0.002), and a decrease in the thickness of LMM in patients suffering from CNSLBP during contraction (p = 0.006), during rest (p = 0.018). The cross‐section area of the LMM showed no statistically significant differences during rest on the right and left sides (p = 0.827, 0.220 respectively) and contraction (p = 0.160, 0.278 respectively) between patients and healthy subjects.ConclusionMotor control and the morphology of LMM in patients with CNSLBP with CLI may provide insight into the mechanisms of underlying pain and their effect on muscle function and structure.

2024-01-01·Egyptian journal of Immunology

Evaluation of Interleukin-17 A Levels in Patients with Breast Carcinoma

Article

作者: Kamel, Mahmoud M ; Gohar, Noha M ; Moaz, Inas ; El-Batal, Heba M

Breast cancer is a highly common form of cancer that impacts a considerable proportion of women on a global scale. Interleukin 17A (IL-17A) is a cytokine that has both anti-tumor and pro-tumor effects, which can vary depending on the specific tumor microenvironment. The aim of this study was to determine whether IL-17A can be used as a biomarker for diagnosis of breast cancer. Therefore, we compared concentrations of serum IL-17A in patients suffering from breast carcinoma and normal control women by an enzyme-linked immunosorbent assay (ELISA). This study included 86 women, 44 patients that were diagnosed with breast carcinoma, and 42 normal control women. Serum IL-17A levels in both case and control groups were measured by sandwich ELISA kits. The IL-17A serum level was significantly higher among patients with breast carcinoma than in the control group (p<0.001). The serum IL-17A concentration was significantly higher in estrogen receptor-positive cases than in estrogen receptor-negative cases (p=0.033). The highest levels of IL-17A were detected in patients with stage 2 breast carcinoma rather than stage 3 with no significant correlation. There was no correlation between IL-17A level and tumor size, lymph node invasion, or metastasis in patients with breast cancer. In conclusion, a high level of IL-17A in breast carcinoma patients compared to the control group was detected in our study. It indicates that IL-17A could be a promising biomarker for diagnosis of breast cancer and may play a role in tumor development. High levels of IL-17A were not a predictor of poor prognosis in breast cancer patients as it was not related to tumor size, lymph node invasion, or metastasis.

100 项与 National Liver Institute, Egypt 相关的药物交易

登录后查看更多信息

100 项与 National Liver Institute, Egypt 相关的转化医学

登录后查看更多信息